GlassScriptPhysician profile
Thomas L Bossi
NPI 1346342235
$8,002.03
in general payments reported to CMS, 2019-2025
44 companies · $212 in 2025
The $212 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $854 · 2020: $1,028 · 2021: $1,416 · 2022: $1,557 · 2023: $1,349 · 2024: $1,586 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,067 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,066.89 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,330.18 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $1,188.23 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $549.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $435.60 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $370.44 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $320.78 | 2020-2021 | |
| Pfizer INC. | $292.81 | 2019-2024 | |
| Amgen INC. | $291.24 | 2019-2024 | Repatha, Otezla |
| Astellas Pharma US INC | $237.49 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $232.70 | 2019-2023 | Xarelto |
| Exact Sciences Corporation | $222.23 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $185.98 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $181.61 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $174.53 | 2019-2025 | Breztri, Airsupra |
| Allergan, INC. | $172.16 | 2020 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bossi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.